Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:188 (24 January), doi:10.1136/bmj.328.7433.188
Liza Gibson
London
| The first 150 words of the full text of this article appear below. |
One of Spain's independent drug bulletins, Butlletí Groc, is being sued by Merck Sharp & Dohme for an article that claimed that the company committed scientific fraud in a trial of its cyclo-oxegenase-2 (COX 2) inhibitor rofecoxib (Vioxx). The case opened in Madrid last week.
The company wants the bulletin to retract its article on the Vioxx gastrointestinal outcomes research (VIGOR) trial and publish a new one reproducing text prepared by the company. However, Professor Joan-Ramon Laporte, the bulletin's editor, refuses to do so.
He said: "I feel this is an attack on independent information on drugs. The pharmaceutical industry has almost a monopoly on information on drugs and therapeutics." Professor Laporte claimed that the company's text was "mainly propaganda" for rofecoxib.
The article, entitled "The so called advantages of celecoxib and rofecoxib: scientific fraud," was published in the July-September 2002 issue of the bulletin (
2002;15: 13-5)
-->
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses